OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
March 03, 2024
March 01, 2024
CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.
February 29, 2024
This discussion explores how the management and analysis of vast data generated by advanced analytical technologies are revolutionizing the drug discovery and development process within the biopharma industry.
Webinar Date/Time: Tue, Apr 9, 2024 2:00 PM EDT
February 28, 2024
Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.
February 20, 2024
Webinar Date/Time: Thu, Mar 14, 2024 2:00 PM EDT
February 16, 2024
Webinar Date/Time: Wed, Mar 27, 2024 11:00 AM EDT
February 15, 2024
BioVaxys has acquired the full portfolio of discovery, preclinical, and clinical development-stage assets of the former IMV.
February 12, 2024
Under the new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.
Webinar Date/Time: Tue, Mar 5, 2024 2:00 PM EST